Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of cicletanine in pulmonary arterial hypertension
2008-007455-26Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Cicletanine dose-ranging with Placebo (2 arms). Primary endpoint: Change from baseline in 6-minute walk distance at 12 weeks. Started Mar 2009; status: terminated.
02
Drugs
cicletanine
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2008-007455-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007455-26.